Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01214915 | Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia | PHASE3 | COMPLETED | 53 | — | — | Oct 27, 2010 | Oct 24, 2012 | Jun 9, 2021 | 19 | Japan |
A response was defined as platelet counts to \<600x10\^9/L across consecutive visits for at least 4 weeks following at least 3 months of treatment.
| Arm | Type | Description |
|---|---|---|
| Anagrelide Hydrochloride | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Anagrelide Hydrochloride | DRUG | Subjects will be started at 1.0 mg per day and titrated as necessary. |
Inclusion Criteria: * Subjects must have previously been treated with a cytoreductive therapy and been intolerant or refractory to that therapy. Exclusion Criteria: * Subjects should not have any other underlying conditions or medications that would confound the study analysis or interact with th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Bomedemstat, Hydroxyurea, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b |
| Incyte Corporation | INCY | 1 | PHASE1 | INCB057643, Ruxolitinib |